[1]
LYELL A, Toxic epidermal necrolysis: an eruption resembling scalding of the skin. The British journal of dermatology. 1956 Nov;
[PubMed PMID: 13374196]
[2]
Bastuji-Garin S,Rzany B,Stern RS,Shear NH,Naldi L,Roujeau JC, Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of dermatology. 1993 Jan;
[PubMed PMID: 8420497]
Level 3 (low-level) evidence
[3]
Pejčić AV, Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases. International journal of dermatology. 2021 Jan;
[PubMed PMID: 32808293]
Level 3 (low-level) evidence
[4]
Moshfeghi M,Mandler HD, Ciprofloxacin-induced toxic epidermal necrolysis. The Annals of pharmacotherapy. 1993 Dec;
[PubMed PMID: 8305780]
[5]
Mockenhaupt M,Viboud C,Dunant A,Naldi L,Halevy S,Bouwes Bavinck JN,Sidoroff A,Schneck J,Roujeau JC,Flahault A, Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. The Journal of investigative dermatology. 2008 Jan;
[PubMed PMID: 17805350]
[6]
Roujeau JC,Kelly JP,Naldi L,Rzany B,Stern RS,Anderson T,Auquier A,Bastuji-Garin S,Correia O,Locati F, Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. The New England journal of medicine. 1995 Dec 14;
[PubMed PMID: 7477195]
[7]
Shen MH,Liu MT,Chung WH,Lu CW, Toxic epidermal necrolysis induced by human herpesvirus 7 treated with a tumor necrosis factor-α inhibitor. The Journal of dermatology. 2020 Oct;
[PubMed PMID: 32686137]
[8]
Wu J,Lee YY,Su SC,Wu TS,Kao KC,Huang CC,Chang WC,Yang CH,Chung WH, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. The British journal of dermatology. 2015 Nov;
[PubMed PMID: 26218033]
[9]
Chahal D,Aleshin M,Turegano M,Chiu M,Worswick S, Vaccine-induced toxic epidermal necrolysis: A case and systematic review. Dermatology online journal. 2018 Jan 15;
[PubMed PMID: 29469759]
Level 3 (low-level) evidence
[10]
Narang I,Panthagani AP,Lewis M,Chohan B,Ferguson A,Nambi R, COVID-19-induced toxic epidermal necrolysis. Clinical and experimental dermatology. 2021 Jul;
[PubMed PMID: 33511662]
[11]
Lagziel T,Quiroga L,Ramos M,Hultman CS,Asif M, Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). Cureus. 2020 May 19;
[PubMed PMID: 32455090]
Level 3 (low-level) evidence
[12]
Hsu DY,Brieva J,Silverberg NB,Silverberg JI, Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. The Journal of investigative dermatology. 2016 Jul;
[PubMed PMID: 27039263]
[13]
Rzany B,Mockenhaupt M,Baur S,Schröder W,Stocker U,Mueller J,Holländer N,Bruppacher R,Schöpf E, Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. Journal of clinical epidemiology. 1996 Jul;
[PubMed PMID: 8691227]
[14]
Frey N,Jossi J,Bodmer M,Bircher A,Jick SS,Meier CR,Spoendlin J, The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. The Journal of investigative dermatology. 2017 Jun;
[PubMed PMID: 28202399]
[15]
Sunaga Y,Kurosawa M,Ochiai H,Watanabe H,Sueki H,Azukizawa H,Asada H,Watanabe Y,Yamaguchi Y,Aihara M,Mizukawa Y,Ohyama M,Hama N,Abe R,Hashizume H,Nakajima S,Nomura T,Kabashima K,Tohyama M,Takahashi H,Mieno H,Ueta M,Sotozono C,Niihara H,Morita E,Kokaze A, The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. Journal of dermatological science. 2020 Dec;
[PubMed PMID: 33046331]
Level 2 (mid-level) evidence
[16]
Struck MF,Hilbert P,Mockenhaupt M,Reichelt B,Steen M, Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive care medicine. 2010 Jan;
[PubMed PMID: 19787334]
[17]
Hung SI,Chung WH,Liou LB,Chu CC,Lin M,Huang HP,Lin YL,Lan JL,Yang LC,Hong HS,Chen MJ,Lai PC,Wu MS,Chu CY,Wang KH,Chen CH,Fann CS,Wu JY,Chen YT, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America. 2005 Mar 15;
[PubMed PMID: 15743917]
[18]
Locharernkul C,Loplumlert J,Limotai C,Korkij W,Desudchit T,Tongkobpetch S,Kangwanshiratada O,Hirankarn N,Suphapeetiporn K,Shotelersuk V, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008 Dec;
[PubMed PMID: 18637831]
[19]
Man CB,Kwan P,Baum L,Yu E,Lau KM,Cheng AS,Ng MH, Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007 May;
[PubMed PMID: 17509004]
[20]
Abe R, Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. Journal of dermatological science. 2008 Dec;
[PubMed PMID: 18657400]
[21]
Viard I,Wehrli P,Bullani R,Schneider P,Holler N,Salomon D,Hunziker T,Saurat JH,Tschopp J,French LE, Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (New York, N.Y.). 1998 Oct 16;
[PubMed PMID: 9774279]
[22]
Chung WH,Hung SI,Yang JY,Su SC,Huang SP,Wei CY,Chin SW,Chiou CC,Chu SC,Ho HC,Yang CH,Lu CF,Wu JY,Liao YD,Chen YT, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature medicine. 2008 Dec;
[PubMed PMID: 19029983]
[23]
Paquet P,Piérard GE, Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes. Skin pharmacology and physiology. 2007;
[PubMed PMID: 17139195]
[24]
Hayes JD,Pulford DJ, The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical reviews in biochemistry and molecular biology. 1995;
[PubMed PMID: 8770536]
[25]
Schwartz RA,McDonough PH,Lee BW, Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. Journal of the American Academy of Dermatology. 2013 Aug;
[PubMed PMID: 23866878]
[26]
Pereira FA,Mudgil AV,Rosmarin DM, Toxic epidermal necrolysis. Journal of the American Academy of Dermatology. 2007 Feb;
[PubMed PMID: 17224365]
[27]
French LE, Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergology international : official journal of the Japanese Society of Allergology. 2006 Mar;
[PubMed PMID: 17075281]
Level 3 (low-level) evidence
[28]
Brown CS,Defazio JR,An G,O'Connor A,Whitcomb E,Hart J,Gottlieb LJ, Toxic Epidermal Necrolysis with Gastrointestinal Involvement: A Case Report and Review of the Literature. Journal of burn care
[PubMed PMID: 27058583]
Level 3 (low-level) evidence
[29]
Sotozono C,Ueta M,Koizumi N,Inatomi T,Shirakata Y,Ikezawa Z,Hashimoto K,Kinoshita S, Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009 Apr;
[PubMed PMID: 19243825]
[30]
Chang YS,Huang FC,Tseng SH,Hsu CK,Ho CL,Sheu HM, Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007 Feb;
[PubMed PMID: 17251797]
[31]
Bastuji-Garin S,Fouchard N,Bertocchi M,Roujeau JC,Revuz J,Wolkenstein P, SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. The Journal of investigative dermatology. 2000 Aug;
[PubMed PMID: 10951229]
[32]
Wolkenstein PE,Roujeau JC,Revuz J, Drug-induced toxic epidermal necrolysis. Clinics in dermatology. 1998 May-Jun;
[PubMed PMID: 9642534]
[33]
Stingeni L,Bianchi L,Tramontana M,Pigatto PD,Patruno C,Corazza M,Foti C,Fabbrocini G,Micali G,Romita P,Napolitano M,Hansel K, Skin tests in the diagnosis of adverse drug reactions. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. 2020 Oct;
[PubMed PMID: 32938165]
[34]
Seminario-Vidal L,Kroshinsky D,Malachowski SJ,Sun J,Markova A,Beachkofsky TM,Kaffenberger BH,Ergen EN,Mauskar M,Bridges A,Calhoun C,Cardones AR,Chen ST,Chodosh J,Cotliar J,Davis MDP,DeNiro KL,Dominguez AR,Eljure-Téllez J,Femia A,Fox LP,Guda A,Mitchell C,Mostaghimi A,Ortega-Loayza AG,Owen C,Pasieka H,Rahnama-Moghadam S,Saeed HN,Saunderson RB,Shanbhag S,Sharon VR,Strowd L,Venkatesh S,Wanat KA,Wetter DA,Worswick S,Micheletti RG, Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology. 2020 Jun;
[PubMed PMID: 32151629]
[36]
Woolum JA,Bailey AM,Baum RA,Metts EL, A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Advanced emergency nursing journal. 2019 Jan/Mar;
[PubMed PMID: 30702535]
[37]
Koh MJ,Tay YK, An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Current opinion in pediatrics. 2009 Aug;
[PubMed PMID: 19474732]
Level 3 (low-level) evidence
[38]
Boorboor P,Vogt PM,Bechara FG,Alkandari Q,Aust M,Gohritz A,Spies M, Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns : journal of the International Society for Burn Injuries. 2008 Jun;
[PubMed PMID: 17919820]
[39]
Dorafshar AH,Dickie SR,Cohn AB,Aycock JK,O'Connor A,Tung A,Gottlieb LJ, Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plastic and reconstructive surgery. 2008 Jul;
[PubMed PMID: 18594400]
[40]
Huang SH,Wu SH,Sun IF,Lee SS,Lai CS,Lin SD,Lin TM, AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN). Burns : journal of the International Society for Burn Injuries. 2008 Feb;
[PubMed PMID: 17618057]
[41]
Revuz J,Penso D,Roujeau JC,Guillaume JC,Payne CR,Wechsler J,Touraine R, Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Archives of dermatology. 1987 Sep;
[PubMed PMID: 3632000]
[42]
Palmieri TL,Greenhalgh DG,Saffle JR,Spence RJ,Peck MD,Jeng JC,Mozingo DW,Yowler CJ,Sheridan RL,Ahrenholz DH,Caruso DM,Foster KN,Kagan RJ,Voigt DW,Purdue GF,Hunt JL,Wolf S,Molitor F, A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. The Journal of burn care
[PubMed PMID: 11882797]
[43]
Ririe MR,Blaylock RC,Morris SE,Jung JY, Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis. Journal of the American Academy of Dermatology. 2013 Aug;
[PubMed PMID: 23673282]
[44]
Chaidemenos GC,Chrysomallis F,Sombolos K,Mourellou O,Ioannides D,Papakonstantinou M, Plasmapheresis in toxic epidermal necrolysis. International journal of dermatology. 1997 Mar;
[PubMed PMID: 9159011]
[45]
Kohanim S,Palioura S,Saeed HN,Akpek EK,Amescua G,Basu S,Blomquist PH,Bouchard CS,Dart JK,Gai X,Gomes JA,Gregory DG,Iyer G,Jacobs DS,Johnson AJ,Kinoshita S,Mantagos IS,Mehta JS,Perez VL,Pflugfelder SC,Sangwan VS,Sippel KC,Sotozono C,Srinivasan B,Tan DT,Tandon R,Tseng SC,Ueta M,Chodosh J, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease. The ocular surface. 2016 Jan;
[PubMed PMID: 26549248]
[46]
Bachot N,Roujeau JC, Differential diagnosis of severe cutaneous drug eruptions. American journal of clinical dermatology. 2003;
[PubMed PMID: 12862499]
[47]
Roujeau JC,Stern RS, Severe adverse cutaneous reactions to drugs. The New England journal of medicine. 1994 Nov 10;
[PubMed PMID: 7794310]
[48]
Letko E,Papaliodis DN,Papaliodis GN,Daoud YJ,Ahmed AR,Foster CS, Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Annals of allergy, asthma
[PubMed PMID: 15875523]
[49]
Mukasa Y,Craven N, Management of toxic epidermal necrolysis and related syndromes. Postgraduate medical journal. 2008 Feb;
[PubMed PMID: 18322124]
[50]
Meneux E,Wolkenstein P,Haddad B,Roujeau JC,Revuz J,Paniel BJ, Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstetrics and gynecology. 1998 Feb;
[PubMed PMID: 9469290]
Level 2 (mid-level) evidence
[51]
Lebargy F,Wolkenstein P,Gisselbrecht M,Lange F,Fleury-Feith J,Delclaux C,Roupie E,Revuz J,Roujeau JC, Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive care medicine. 1997 Dec;
[PubMed PMID: 9470079]
[52]
Lee HY,Walsh SA,Creamer D, Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. The British journal of dermatology. 2017 Oct;
[PubMed PMID: 28144971]
[53]
Lam A,Randhawa I,Klaustermeyer W, Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. Allergology international : official journal of the Japanese Society of Allergology. 2008 Sep;
[PubMed PMID: 18566552]
[54]
O'Reilly P,Kennedy C,Meskell P,Coffey A,Delaunois I,Dore L,Howard S,Ramsay B,Scanlon C,Wilson DM,Whelan B,Ryan S, The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: a Critically Appraised Topic. The British journal of dermatology. 2020 Sep;
[PubMed PMID: 31792924]
[55]
Creamer D,Walsh SA,Dziewulski P,Exton LS,Lee HY,Dart JK,Setterfield J,Bunker CB,Ardern-Jones MR,Watson KM,Wong GA,Philippidou M,Vercueil A,Martin RV,Williams G,Shah M,Brown D,Williams P,Mohd Mustapa MF,Smith CH, U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. The British journal of dermatology. 2016 Jun;
[PubMed PMID: 27317286]